Journal of Asthma and Allergy (Jun 2022)
Management of Uncontrolled Asthma: A Framework for Novel and Legacy Biologic Treatments
Abstract
Laren D Tan,1,2 Nolan Nguyen,3 Abdullah Alismail,2 Mario Castro4 1Department of Internal Medicine, School of Medicine, Loma Linda University Health, Loma Linda, CA, USA; 2Department of Cardiopulmonary Sciences, School of Allied Health Professions, Loma Linda, CA, USA; 3Department of Biological Sciences, University of California, San Diego, CA, USA; 4Department of Medicine, University of Kansas School of Medicine, Kansas City, KS, USACorrespondence: Laren D Tan, Email [email protected]: Asthma continues to be a complex respiratory disease to control for many despite optimal standard inhaler therapy. The increased dependence on steroid-sparing biologic treatments in the 21st century has created a dilemma between identifying the patient’s intrinsic biomarkers and their “life markers.” With Tezepelumab being the most recent FDA-approved biologic for asthma, it is even more critical for asthma specialists to better understand and establish a framework to determine which biologic would work best for their patients. While cost and payor approvals limit access to certain asthma biologics, medical decisions on which biologic to select should be centered around shared decision-making, the rationale for biologic initiation, and critical biologic education to help achieve successful asthma control.Keywords: severe asthma, Tezepelumab, asthma biologic, shared decision making, asthma
